Biomea Fusion, Inc. reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on oral small-molecule therapies for diabetes, obesity and related metabolic diseases. Its updates center on icovamenib, an investigational oral covalent menin inhibitor being evaluated in type 1 and type 2 diabetes, and BMF-650, an investigational oral GLP-1 receptor agonist candidate for obesity.
Recurring announcements include COVALENT trial results and study initiations, measures of beta-cell function, C-peptide, glycemic control and safety, scientific presentations at diabetes and metabolic-disease meetings, investor-conference activity, and periodic financial results with pipeline updates.
Biomea Fusion (BMEA) has terminated its proposed public offering of securities announced on September 22, 2026, citing market conditions.
Management determined that current market conditions are not conducive to completing an offering on terms viewed as in the best interests of stockholders. No securities were sold in connection with the proposed offering. The now-terminated offering had been planned under an effective Form S-3 shelf registration statement and a preliminary prospectus supplement filed on September 22, 2026.
Biomea Fusion (BMEA) has commenced an underwritten public offering of common stock and, for certain investors, pre-funded warrants to purchase common shares.
The company plans to grant the underwriter a 30-day option to buy up to an additional 15% of the total number of shares and pre-funded warrants. All securities in the proposed offering will be sold by Biomea, and completion, size and terms remain subject to market and other conditions. Konik Capital Partners, a division of T.R. Winston & Company, is acting as sole underwriter. The offering is being made under an effective shelf registration statement on Form S-3 filed August 5, 2025 and declared effective August 15, 2025.
Biomea Fusion (BMEA) will participate in two investor conferences in September 2026 in New York. Management will attend Citi's 2026 Biopharma Back to School Conference for one-on-one investor meetings on September 10, 2026. The company will also present at the H.C. Wainwright 28th Annual Global Investment Conference at 11:00 a.m. ET on September 15, 2026, and hold additional one-on-one meetings. An audio webcast and replay of the H.C. Wainwright presentation will be available on Biomea’s website under Investors & Media.
Biomea Fusion (Nasdaq: BMEA) announced completion of enrollment in COVALENT-211, a randomized, double-blind, placebo-controlled Phase II trial of icovamenib in insulin-deficient type 2 diabetes patients inadequately controlled on standard antihyperglycemic therapies. The study enrolled 64 participants across 18 sites, randomized 2:1 to icovamenib 100 mg once daily or placebo for 12 weeks, followed by a 40-week off-treatment period through Week 52. The primary endpoint is assessed at Week 26, with topline data expected in Q1 2027.
COVALENT-212, targeting T2D patients not at glycemic targets despite GLP-1–based therapy, continues enrolling and is expected to complete enrollment before year end, with 26-week primary endpoint data anticipated in Q2 2027. Both trials leverage Phase II COVALENT-111 data, where icovamenib showed durable, placebo-adjusted HbA1c reductions up to 1.5% and 1.8% at Week 52 and was generally well tolerated without treatment-related serious adverse events or discontinuations.
Biomea Fusion (Nasdaq: BMEA) reported dosing the first participant in a new arm of the OPAL study, a multi-arm open-label adaptive platform trial run with the University of Leicester and Leicester Diabetes Centre. The experimental arm tests Biomea’s investigational small molecule icovamenib (100 mg once daily for 12 weeks) combined with low-dose semaglutide (24 weeks) versus low-dose semaglutide alone in overweight or obese adults without type 2 diabetes.
This randomized, double-blind arm will enroll 64 participants, allocated 1:1. The study will assess whether adding icovamenib can enhance weight loss and will measure effects on physical function, body composition, muscle health, and metabolic outcomes, with the primary endpoint at Week 24. Preclinical data showed icovamenib improved semaglutide-driven weight loss, favoring fat loss while preserving lean mass and modulating GLP-1 expression and adipose metabolism.
Biomea Fusion (Nasdaq: BMEA) reported second quarter 2026 results and clinical updates for its diabetes and obesity programs. Cash, cash equivalents and restricted cash were $35.2 million as of June 30, 2026, with a projected runway into the second quarter of 2027. Net loss attributable to common stockholders was $8.3 million for Q2 2026 versus $20.7 million a year earlier; first-half 2026 net loss was $20.7 million versus $50.0 million in 2025.
R&D expenses fell to $9.1 million for Q2 (from $16.6 million), and G&A to $3.6 million (from $4.7 million), largely due to lower headcount and external costs. Phase II T2D trials COVALENT-211 and COVALENT-212 are enrolling, with 26-week primary endpoint data expected in Q1 2027 and Q2 2027, respectively. In T1D, 52-week COVALENT-112 data showed a 52% increase in mean C-peptide AUC at Week 12 in a small subgroup and durable preservation through Week 52, supporting a planned Phase II trial with extended dosing and possible combination therapy.
Biomea also advanced obesity initiatives, including the Phase I GLP-131 (BMF-650) trial with 28-day weight reduction data expected in Q3 2026, and a new research collaboration with the University of Leicester to study icovamenib plus semaglutide in a Phase II obesity trial.
Biomea Fusion (Nasdaq:BMEA) reported new icovamenib data at the ADA 86th Scientific Sessions and expanded its Phase I BMF-650 study.
Clinical and translational results show improved HbA1c and C-peptide in T1D/T2D, activation of metabolic pathways linked to fat loss and muscle preservation, and support for combination with GLP-1 RAs. An added BMF-650 cohort will test rapid titration (200→400 mg QD) and weight-loss potential, with 28-day data expected in Q3 2026.
Biomea Fusion (Nasdaq:BMEA) will collaborate with the University of Leicester to evaluate investigational menin inhibitor icovamenib plus semaglutide in obesity within the OPAL platform trial. The randomized, double-blind arm will study body weight, composition, muscle health, physical function, and metabolic outcomes in overweight or obese adults without type 2 diabetes.
Biomea Fusion (Nasdaq:BMEA) reported first quarter 2026 results and pipeline progress in diabetes and obesity.
Chronic toxicology studies for icovamenib were completed, Phase II T2D trials (COVALENT-211/212) are enrolling, and 52-week Phase II T1D data showed preserved C-peptide with favorable safety. Phase I BMF-650 obesity trial is ongoing. Cash was $45.1M with runway into Q1 2027; Q1 net loss was $12.4M, with R&D and G&A expenses significantly lower year-over-year.
Biomea Fusion (Nasdaq: BMEA) announced three late-breaking poster presentations of icovamenib at the American Diabetes Association 86th Scientific Sessions, June 5–8, 2026 in New Orleans. Presentations cover type 1 and type 2 diabetes and mechanisms supporting beta cell function and metabolic health.
All posters will be embargoed until June 5, 2026 at 6:30 PM CT and then posted on Diabetes journal and Biomea’s Investors & Media site. Session dates and presenters are scheduled for June 7, 2026.